Renal-cell carcinoma (RCC) is the most common type of kidney cancer, accounting for >100,000 annual deaths globally and rising in incidence. With several approved products, immunotherapy plays an important role in the management of RCC, and its significance is expected to increase. We are looking for articles investigating:
- RCC immunotherapy in clinical use and in clinical trials
- Novel approaches to RCC immunotherapy
- (Neo)adjuvant immunotherapy and combination regimens
- RCC vaccines and personalized immunotherapies
- Biomarkers and predictive factors
- Preclinical models, trial design and regulatory issues
Submission information:
- Select "Immunotherapy of RCC" when submitting your paper to the Submission Portal
- Research papers, Reviews and Commentaries will be considered for publication
- Papers will be published online as they are accepted
